Vixiar Medical develops non-invasive, cost-effective technologies for monitoring cardiopulmonary diseases, with a focus on heart failure. Its first product, Indicor, is a handheld point-of-care device and digital platform for early detection and monitoring of worsening heart failure. The company says the device is designed for use across hospitals, physician offices, skilled nursing facilities and patient homes. Vixiar is a spinout of Johns Hopkins and is headquartered in Baltimore, Maryland. Proceeds from the recent financing will be used to complete an ongoing clinical trial and to prepare regulatory submissions. Leadership cited the large unmet need in heart failure monitoring and asserted advantages over competing technologies. Vixiar Medical is an Annapolis, MD–based company dedicated to developing non-invasive devices and systems for monitoring cardiopulmonary diseases. Led by CEO Kevin Thibodeau, the company is a spinout of Johns Hopkins. Vixiar’s first product, Indicor™, is a handheld point-of-care device and digital platform for monitoring worsening heart failure. The company raised over $1.5m in seed financing from investors including the Abell Foundation, Maryland’s TEDCO and backers from Asia, Europe and the US. Vixiar intends to use the proceeds to complete regulatory submissions and to fund final engineering and initial production of Indicor. The company focuses on conditions with significant clinical and economic burden.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2019